The company can now perform the test on samples from New York residents with advanced prostate cancer to help guide the choice of either hormonal or chemotherapy.
The firm's EpiSwitch test for blood-based diagnosis of prostate cancer will be evaluated as part of the ongoing PROSTAGRAM trial.
With deep learning software running on a supercomputer, Paige.AI is developing pathology technology that learns from large-scale digital image datasets.
The researchers said that their proof-of-concept microfluidic platform is 1,000 times more sensitive than a traditional ELISA.
The company's revenues in the quarter rose to $221.9 million from $161.0 million in Q4 2017, but it missed the consensus Wall Street estimate of $245.3 million.
Company officials said they expect the firm's growth momentum to continue in 2019, with increased penetration both in the US and in European markets.
The breath-based biopsy firm is collaborating with Renji Hospital to conduct a clinical trial into the early detection of lung cancer in China.
Decipher — formerly GenomeDx Biosciences — will help Dendreon identify patients who are likely to respond to its prostate cancer therapy Provenge.
The test measures a number of protein biomarkers, including a proprietary antibody, to diagnose prostate cancer and determine its aggressiveness.
As part of the agreement, LifeLabs will serve as an exclusive distributor for MDxHealth's non-invasive liquid biopsy prostate cancer assay In Canada.